RDUS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RDUS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Radius Health's average Accounts Receivable for the three months ended in Jun. 2022 was $28.3 Mil. Radius Health's Revenue for the three months ended in Jun. 2022 was $58.3 Mil. Hence, Radius Health's Days Sales Outstanding for the three months ended in Jun. 2022 was 44.26.
The historical rank and industry rank for Radius Health's Days Sales Outstanding or its related term are showing as below:
Radius Health's Days Sales Outstanding increased from Jun. 2021 (43.99) to Jun. 2022 (44.26).
The historical data trend for Radius Health's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Radius Health Annual Data | |||||||||||||||||||||
Trend | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | |||||||||||
Days Sales Outstanding | Get a 7-Day Free Trial | 73.31 | 38.98 | 42.17 | 33.34 | 34.65 |
Radius Health Quarterly Data | ||||||||||||||||||||
Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | |
Days Sales Outstanding | Get a 7-Day Free Trial | 43.99 | 40.30 | 34.97 | 56.70 | 44.26 |
For the Drug Manufacturers - Specialty & Generic subindustry, Radius Health's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Radius Health's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Radius Health's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Accounts Receivable can be measured by Days Sales Outstanding.
Radius Health's Days Sales Outstanding for the fiscal year that ended in Dec. 2021 is calculated as
Days Sales Outstanding (A: Dec. 2021 ) | |||||||||
= | Average Accounts Receivable | / | Revenue | * | Days in Period | ||||
= | ( (Accounts Receivable (A: Dec. 2020 ) | + | Accounts Receivable (A: Dec. 2021 )) | / | count ) | / | Revenue (A: Dec. 2021 ) | * | Days in Period |
= | ( (20.31 | + | 23.355) | / | 2 ) | / | 229.973 | * | 365 |
= | 21.8325 | / | 229.973 | * | 365 | ||||
= | 34.65 |
Radius Health's Days Sales Outstanding for the quarter that ended in Jun. 2022 is calculated as:
Days Sales Outstanding (Q: Jun. 2022 ) | |||||||||
= | Average Accounts Receivable | / | Revenue | * | Days in Period | ||||
= | ( (Accounts Receivable (A: Mar. 2022 ) | + | Accounts Receivable (A: Jun. 2022 )) | / | count ) | / | Revenue (A: Jun. 2022 ) | * | Days in Period |
= | ( (30.28 | + | 26.26) | / | 2 ) | / | 58.285 | * | 365 / 4 |
= | 28.27 | / | 58.285 | * | 365 / 4 | ||||
= | 44.26 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Radius Health (NAS:RDUS) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Thank you for viewing the detailed overview of Radius Health's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.
Willard H Dere | director | ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799 |
Jean Pierre Garnier | director | UNITED TECHNOLOGIES CORP, 10 FARM SPRINGS ROAD, FARMINGTON CT 06032 |
Von Eschenbach Andrew C. | director | C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807 |
Jennifer Jarrett | director | C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105 |
Cathy Friedman | director | C/O INNOVIVA, INC., 2000 SIERRA POINT PARKWAY, SUITE 500, BRISBANE CA 94005 |
Machelle Sanders | director | C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560 |
G. Kelly Martin | director, officer: CEO and President | C/O NOVAN, INC., 4105 HOPSON RD, MORRISVILLE NC 27560 |
Sean Murphy | director | C/O NOVAN, INC., 4222 EMPEROR BOULEVAND, SUITE 200, DURHAM NC 27703 |
Owen Hughes | director | C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, BOSTON MA 02139 |
Elizabeth Messersmith | officer: Senior Vice President | 22 BOSTON WHARF ROAD 7TH FLOOR BOSTON MA 02210 |
Danielle Holtschlag | officer: Vice President, Sales | 22 BOSTON WHARF ROAD 7TH FLOOR BOSTON MA 02210 |
Chhaya Shah | officer: Chief Business Officer | 22 BOSTON WHARF ROAD 7TH FLOOR BOSTON MA 02210 |
Susan Vissers Lisa | director | 22 BOSTON WHARF ROAD 7TH FLOOR BOSTON MA 02210 |
Rubric Capital Management Lp | 10 percent owner | 155 EAST 44TH ST, SUITE 1630, NEW YORK NY 10017 |
Biotech Target N V | 10 percent owner | ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000 |
From GuruFocus
By Business Wire Business Wire • 05-03-2022
By Business Wire • 12-18-2023
By Business Wire Business Wire • 02-01-2022
By Business Wire Business Wire • 06-12-2023
By Business Wire Business Wire • 01-18-2023
By GuruFocus Research • 10-25-2023
By Business Wire Business Wire • 06-21-2023
By Business Wire Business Wire • 03-20-2023
By Business Wire • 09-29-2023
By Business Wire • 07-26-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.